Evidence map›Paper›PMID 37766159›Full record

ArticleVaccines2023

Safety of the Administration of an Inactivated PCV2a/PCV2b/

Elena Pérez, Cristina Venegas-Vargas, Andrea Heinz, Megan Smutzer, Lucas P Taylor, Yvette Diamondidis, Nevena Mangarova, Tara Hansen, José Angulo, Meggan Bandrick and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Elena PérezZoetis Manufacturing & Research Spain S.L., Ctra Camprodon s/n, 17813 Vall de Bianya, Spain.
Cristina Venegas-VargasZoetis Inc., 333 Portage St, Kalamazoo, MI 49007, USA.
Andrea HeinzZoetis Inc., 333 Portage St, Kalamazoo, MI 49007, USA.
Megan SmutzerZoetis Inc., 333 Portage St, Kalamazoo, MI 49007, USA.
Lucas P TaylorZoetis Inc., 333 Portage St, Kalamazoo, MI 49007, USA.
Yvette DiamondidisZoetis Inc., 333 Portage St, Kalamazoo, MI 49007, USA.
Nevena MangarovaZoetis Belgium S.A., 20 Mercuriusstraat, 1930 Zaventem, Belgium.
Tara HansenZoetis Inc., 601 West Cornhusker Hwy, Lincoln, NE 68521, USA.
José AnguloZoetis Inc., Parsippany, NJ 07054, USA.
Meggan BandrickZoetis Inc., 333 Portage St, Kalamazoo, MI 49007, USA.
Monica BalaschZoetis Manufacturing & Research Spain S.L., Ctra Camprodon s/n, 17813 Vall de Bianya, Spain.
Zoetis (United States) · USZoetis (Belgium) · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Porcine Circovirus type 2 (PCV2) vaccination of gilts during acclimation has become a routine practice in commercial pig farms to homogenize herd immunity to PCV2 and reduce the impact of diseases associated with PCV2 infection, namely reproductive, respiratory, systemic, and other PCV2-associated diseases. The periodic mass vaccination of sows, with the same objectives, is also common. To ensure mass vaccination is an appropriate health management tool, demonstrating that the vaccine is safe in different sow/gilt physiological stages is necessary. The objective of the present studies was to evaluate safety of a PCV2a/PCV2b/

Indexed as

gilt developmentporcine circovirus diseasesporcine circovirus vaccines

Identifiers

PMID37766159
PMCPMC10537677
OpenAlexW4386743107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.